Osteogenic Growth Peptide (10-14)是具有活性的成骨生长肽（OGP）的C端截短的五肽片段，是一种Src kinase（Src）抑制剂。
Cas No.:105250-85-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Osteogenic Growth Peptide (10-14) is a truncated pentapeptide fragment of the active osteogenic growth peptide (OGP) and is a Src kinase (Src) inhibitor [1-2]. Osteogenic Growth Peptide (10-14) binds to the OGP receptor and activates the Gi protein-MAP kinase signaling pathway [3]. Osteogenic Growth Peptide (10-14) is a potent mitogen and bone formation and hematopoietic stimulator, which can be used to treat osteoporosis and periodontitis [4].
In vitro, Osteogenic Growth Peptide (10-14) (0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days) treated human periodontal ligament stem cells (hPDLSCs), and at low concentrations (0.01, 0.1, and 1nM), it significantly enhanced cell proliferation and osteogenic differentiation potential, while at concentrations of 10 and 100nM, there was no related response [5]. Osteogenic Growth Peptide (10-14) (0.1nM; 7-21 days) treatment significantly promoted osteogenic differentiation of bone marrow mesenchymal stem cells (MSCs), inhibited adipocyte formation, increased alkaline phosphatase (ALP) activity and mineralization nodules formation, and stimulated osteoblast-specific mRNA expression of nuclear factor 1 (cbfa1), and inhibited adipocyte-specific mRNA expression of peroxisome proliferator-activated receptor gamma-2 (PPARγ2) [6].
In vivo, Osteogenic Growth Peptide (10-14) (1nmol/kg/day; 35 days; s.c.) could significantly alleviate bone loss in female mice that underwent ovarian removal (OVX) 30 days before the start of anabolic therapy, and increase the number of osteogenic cells in the mice [7].
References:
[1] Chen YC, et al. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632.
[2] Battolla B, et al. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.
[3] Chen Z, et al. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080.
[4] Fazzi R, et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1)
[5] Purbantoro S D, Osathanon T, Nantavisai S, et al. Osteogenic growth peptide enhances osteogenic differentiation of human periodontal ligament stem cells[J]. Heliyon, 2022, 8(7).
[6] Chen ZX, Chang M, Peng YL, et al. Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes. Regul Pept. 2007;142(1-2):16-23.
[7] Bab I, Chorev M. Osteogenic growth peptide: from concept to drug design[J]. Peptide Science: Original Research on Biomolecules, 2002, 66(1): 33-48.
Osteogenic Growth Peptide (10-14)是具有活性的成骨生长肽（OGP）的C端截短的五肽片段，是一种Src kinase（Src）抑制剂 [1-2]。Osteogenic Growth Peptide (10-14)与OGP受体结合，并激活细胞内的Gi蛋白-MAP激酶信号通路 [3]。成骨生长肽（10-14）是一种强效的有丝分裂原和骨生成及造血刺激剂，可用于治疗骨质疏松症和牙周炎 [4]。
在体外，Osteogenic Growth Peptide (10-14)（0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days）处理人牙周膜干细胞（hPDLSCs），在低浓度下（0.01、0.1和1nM）显著增强了细胞增殖和成骨分化潜力，而10和100nM浓度下无相关反应 [5]。Osteogenic Growth Peptide (10-14)（0.1nM; 7-21 days）处理显著促进了骨髓间质干细胞（MSCs）的成骨分化，抑制脂肪细胞的形成，增加了碱性磷酸酶（ALP）活性和矿化结节的形成，并刺激核结合因子1（cbfa1）的成骨细胞特异性mRNA表达，并抑制了过氧化物酶增殖物激活受体γ-2（PPARγ2）的脂肪细胞特异性mRNA表达 [6]。
在体内，Osteogenic Growth Peptide (10-14)（1nmol/kg/day; 35 days; s.c.）能够显著缓解在合成代谢治疗开始前30天进行卵巢切除（OVX）的雌性小鼠的骨质流失，增加了小鼠成骨的细胞数量 [7]。
| Cell experiment [1]: | |
Cell lines | Human periodontal ligament stem cells (hPDLSCs) |
Preparation Method | Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS), 1% Antibiotic-Antimycotic, and 1% Glutamax. The isolated cells were incubated at 37°C with 5%CO2. Growth medium was changed every 48h and subcultured at 80% confluence. For Osteogenic Growth Peptide (10-14) treatment, hPDLSCs were cultured with Osteogenic Growth Peptide (10-14) supplemented in culture medium at concentrations of 0.01, 0.1, 1, 10, and 100nM. After Osteogenic Growth Peptide (10-14) treatment for 1, 5, and 7 days in growth medium, live/dead assay was performed by using calcein-AM and propidium iodide (PI) to stain OGP-untreated and -treated hPDLSCs. Cells were seeded at the density of 5 × 103 cells per well in a 24-well culture plate. Carl Zeiss™ Apoptome.2 apparatus-equipped fluorescent microscope was used to evaluate the stained cells. |
Reaction Conditions | 0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days |
Applications | At low concentrations (0.01, 0.1, and 1nM), Osteogenic Growth Peptide (10-14) significantly enhanced cell proliferation, while at concentrations of 10 and 100nM, no corresponding effects were observed. |
References: | |
| Cas No. | 105250-85-9 | SDF | |
| 别名 | OGP(10-14); Historphin | ||
| 分子式 | C24H29N5O7 | 分子量 | 499.52 |
| 溶解度 | DMSO : 8.93 mg/mL (17.88 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0019 mL | 10.0096 mL | 20.0192 mL |
| 5 mM | 400.4 μL | 2.0019 mL | 4.0038 mL |
| 10 mM | 200.2 μL | 1.001 mL | 2.0019 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet